Similar to wild-type CD33, our experiments in engineered acute leukemia cell lines document that the CD33∆E2 variant is internalized, and could thus also serve as target for CD33-directed therapeutics that depend on intracellular delivery of a toxic payload. This evidence concerns the gene CD33 and acute leukemia.